JP2024045183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024045183A5 JP2024045183A5 JP2024000732A JP2024000732A JP2024045183A5 JP 2024045183 A5 JP2024045183 A5 JP 2024045183A5 JP 2024000732 A JP2024000732 A JP 2024000732A JP 2024000732 A JP2024000732 A JP 2024000732A JP 2024045183 A5 JP2024045183 A5 JP 2024045183A5
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- composition
- liposomes
- therapeutic
- lyophilization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 36
- 239000002502 liposome Substances 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 20
- 238000004108 freeze drying Methods 0.000 claims 14
- 229940039227 diagnostic agent Drugs 0.000 claims 11
- 239000000032 diagnostic agent Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 10
- 239000002577 cryoprotective agent Substances 0.000 claims 6
- 235000012000 cholesterol Nutrition 0.000 claims 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 4
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- 230000000717 retained effect Effects 0.000 claims 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- 229960000684 cytarabine Drugs 0.000 claims 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 3
- 229960000975 daunorubicin Drugs 0.000 claims 3
- 150000002016 disaccharides Chemical class 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 239000000155 melt Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 125000000185 sucrose group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000005192 partition Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550047P | 2011-10-21 | 2011-10-21 | |
| US61/550,047 | 2011-10-21 | ||
| JP2019172314A JP2020007367A (ja) | 2011-10-21 | 2019-09-20 | 凍結乾燥リポソーム |
| JP2021196626A JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196626A Division JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024045183A JP2024045183A (ja) | 2024-04-02 |
| JP2024045183A5 true JP2024045183A5 (https=) | 2024-05-10 |
Family
ID=48141268
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537142A Active JP6133308B2 (ja) | 2011-10-21 | 2012-10-15 | 凍結乾燥リポソーム |
| JP2017074348A Active JP6359717B2 (ja) | 2011-10-21 | 2017-04-04 | 凍結乾燥リポソーム |
| JP2018095127A Active JP6592556B2 (ja) | 2011-10-21 | 2018-05-17 | 凍結乾燥リポソーム |
| JP2019172314A Pending JP2020007367A (ja) | 2011-10-21 | 2019-09-20 | 凍結乾燥リポソーム |
| JP2021196626A Active JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
| JP2024000732A Pending JP2024045183A (ja) | 2011-10-21 | 2024-01-05 | 凍結乾燥リポソーム |
Family Applications Before (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537142A Active JP6133308B2 (ja) | 2011-10-21 | 2012-10-15 | 凍結乾燥リポソーム |
| JP2017074348A Active JP6359717B2 (ja) | 2011-10-21 | 2017-04-04 | 凍結乾燥リポソーム |
| JP2018095127A Active JP6592556B2 (ja) | 2011-10-21 | 2018-05-17 | 凍結乾燥リポソーム |
| JP2019172314A Pending JP2020007367A (ja) | 2011-10-21 | 2019-09-20 | 凍結乾燥リポソーム |
| JP2021196626A Active JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10028912B2 (https=) |
| EP (2) | EP3572071A1 (https=) |
| JP (6) | JP6133308B2 (https=) |
| KR (5) | KR102452305B1 (https=) |
| CN (2) | CN108853031A (https=) |
| AU (1) | AU2012326370C9 (https=) |
| BR (1) | BR112014009305B1 (https=) |
| CA (1) | CA2852777C (https=) |
| DK (1) | DK2768484T3 (https=) |
| ES (1) | ES2750368T3 (https=) |
| FR (1) | FR19C1063I2 (https=) |
| HR (1) | HRP20191683T1 (https=) |
| HU (2) | HUE045978T2 (https=) |
| IL (1) | IL232161B (https=) |
| LU (1) | LUC00135I2 (https=) |
| NL (1) | NL301016I2 (https=) |
| NO (1) | NO2019041I1 (https=) |
| PL (1) | PL2768484T3 (https=) |
| PT (1) | PT2768484T (https=) |
| RU (1) | RU2648753C2 (https=) |
| SI (1) | SI2768484T1 (https=) |
| WO (1) | WO2013059133A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3572071A1 (en) * | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
| IL292567B2 (en) | 2013-08-13 | 2025-06-01 | Univ Northwestern | Peptide conjugated particles |
| WO2016033384A1 (en) | 2014-08-28 | 2016-03-03 | The General Hospital Corporation | Injectable slurries and methods of manufacturing and using the same |
| US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| KR20180016347A (ko) * | 2015-04-13 | 2018-02-14 | 파운테인 테크놀로지스 인터내셔널, 엘엘씨 | 초-소형 지질 구조체의 생산을 위한 단일-단계 방법 |
| SMT202100196T1 (it) | 2015-07-22 | 2021-05-07 | Nitto Denko Corp | Composizioni e metodi per forme liofile di nanoparticelle |
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| SG10201913504XA (en) | 2016-02-26 | 2020-03-30 | Massachusetts Gen Hospital | Medical ice slurry production and delivery systems and methods |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN111093623A (zh) * | 2017-07-10 | 2020-05-01 | 免疫疫苗技术公司 | 药物组合物、使用限定大小的脂质囊泡颗粒的制备方法及其用途 |
| EP3856198A4 (en) | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| ES3049663T3 (en) * | 2019-06-28 | 2025-12-17 | Univ Texas | Method of reconstituting liposomal annamycin |
| WO2021016457A1 (en) * | 2019-07-24 | 2021-01-28 | The General Hospital Corporation | Methods of creating a substance with different freezing points by encapsulation |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN115252563B (zh) * | 2022-06-24 | 2024-07-12 | 石药集团中奇制药技术（石家庄）有限公司 | 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法 |
| CN116003493B (zh) * | 2022-12-16 | 2025-02-28 | 常州金远药业制造有限公司 | 一种二价铜离子及阿糖胞苷的回收方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| EP0208764A4 (en) * | 1985-01-11 | 1987-10-08 | Univ California | METHOD FOR PRESERVING LIPOSOMES. |
| CA1256372A (en) | 1985-04-11 | 1989-06-27 | Koichiro Miyazima | Process for producing liposome composition |
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4915951A (en) | 1987-12-03 | 1990-04-10 | California Institute Of Technology | Cryoprotective reagent |
| WO1990003795A1 (en) * | 1988-10-05 | 1990-04-19 | Vestar, Inc. | Method of making liposomes with improved stability during drying |
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| WO1997029782A1 (en) | 1996-02-19 | 1997-08-21 | Nycomed Imaging A/S | Thermally stabilized contrast agent |
| IT1289938B1 (it) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| DE60014093T2 (de) | 1999-07-16 | 2005-02-03 | Alza Corp., Mountain View | Liposomzusammensetzung mit Schutz vor Gefrier-/Aufbau-Schaden |
| US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2462376C (en) | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| CA2467064C (en) | 2001-11-13 | 2011-02-08 | Murray Webb | Lipid carrier compositions with enhanced blood stability |
| DE60222580T2 (de) | 2001-11-13 | 2008-06-12 | Celator Pharmaceuticals, Inc. | Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung |
| EP1585504A4 (en) * | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | Protein stabilized liposomal formulations of pharmaceutical active ingredients |
| US20040265368A1 (en) * | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| WO2005102359A1 (en) * | 2004-04-22 | 2005-11-03 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| US7893338B2 (en) * | 2004-07-15 | 2011-02-22 | Creative Technology Ltd | Method of composing music on a handheld device |
| AU2005302255A1 (en) * | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
| US20090285878A1 (en) * | 2004-11-05 | 2009-11-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
| EP1817005A1 (en) | 2004-11-18 | 2007-08-15 | Celator Pharmaceuticals, Inc. | Method for loading multiple agents into delivery vehicles |
| AU2006306108B2 (en) | 2005-10-25 | 2012-10-04 | Jazz Pharmaceuticals Therapeutics, Inc. | Fixed ratio drug combination treatments for solid tumors |
| WO2007076117A2 (en) | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| EP4046640A1 (en) * | 2007-02-16 | 2022-08-24 | Rotalec IP Holdings LLC | Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders |
| ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| US8486924B2 (en) | 2007-11-28 | 2013-07-16 | Celator Pharmaceuticals, Inc. | Taxane delivery system |
| EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
| PT2508170E (pt) | 2009-12-03 | 2015-10-16 | Shanghai Hengrui Pharm Co Ltd | Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação |
| US20130052259A1 (en) | 2010-02-01 | 2013-02-28 | Yechezkel Barenholz | Liposomes comprising amphipathic drugs and method for their preparation |
| EP3572071A1 (en) * | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
-
2012
- 2012-10-15 EP EP19183846.5A patent/EP3572071A1/en active Pending
- 2012-10-15 KR KR1020217023773A patent/KR102452305B1/ko active Active
- 2012-10-15 KR KR1020227034406A patent/KR20220141906A/ko not_active Ceased
- 2012-10-15 RU RU2014120475A patent/RU2648753C2/ru active
- 2012-10-15 CA CA2852777A patent/CA2852777C/en active Active
- 2012-10-15 BR BR112014009305-9A patent/BR112014009305B1/pt active IP Right Grant
- 2012-10-15 HU HUE12841616A patent/HUE045978T2/hu unknown
- 2012-10-15 AU AU2012326370A patent/AU2012326370C9/en active Active
- 2012-10-15 HR HRP20191683 patent/HRP20191683T1/hr unknown
- 2012-10-15 KR KR1020147012039A patent/KR102024836B1/ko active Active
- 2012-10-15 PL PL12841616T patent/PL2768484T3/pl unknown
- 2012-10-15 PT PT128416161T patent/PT2768484T/pt unknown
- 2012-10-15 US US14/352,662 patent/US10028912B2/en active Active
- 2012-10-15 KR KR1020207013990A patent/KR102284689B1/ko active Active
- 2012-10-15 KR KR1020197027220A patent/KR102113753B1/ko active Active
- 2012-10-15 CN CN201810733439.3A patent/CN108853031A/zh active Pending
- 2012-10-15 CN CN201280059606.1A patent/CN104114156A/zh active Pending
- 2012-10-15 JP JP2014537142A patent/JP6133308B2/ja active Active
- 2012-10-15 ES ES12841616T patent/ES2750368T3/es active Active
- 2012-10-15 SI SI201231668T patent/SI2768484T1/sl unknown
- 2012-10-15 DK DK12841616.1T patent/DK2768484T3/da active
- 2012-10-15 EP EP12841616.1A patent/EP2768484B1/en not_active Revoked
- 2012-10-15 WO PCT/US2012/060293 patent/WO2013059133A1/en not_active Ceased
-
2014
- 2014-04-22 IL IL232161A patent/IL232161B/en active IP Right Grant
-
2017
- 2017-04-04 JP JP2017074348A patent/JP6359717B2/ja active Active
-
2018
- 2018-02-07 US US15/891,170 patent/US10166184B2/en active Active
- 2018-05-17 JP JP2018095127A patent/JP6592556B2/ja active Active
- 2018-11-05 US US16/181,203 patent/US10835492B2/en active Active
-
2019
- 2019-09-20 JP JP2019172314A patent/JP2020007367A/ja active Pending
- 2019-10-10 HU HUS1900047 patent/HUS1900047I1/hu unknown
- 2019-10-23 FR FR19C1063C patent/FR19C1063I2/fr active Active
- 2019-10-24 LU LU00135C patent/LUC00135I2/fr unknown
- 2019-10-25 NL NL301016C patent/NL301016I2/nl unknown
- 2019-11-25 NO NO2019041C patent/NO2019041I1/no unknown
-
2020
- 2020-11-13 US US17/097,530 patent/US20210169803A1/en not_active Abandoned
-
2021
- 2021-12-03 JP JP2021196626A patent/JP7476161B2/ja active Active
-
2022
- 2022-07-13 US US17/812,414 patent/US20230172855A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000732A patent/JP2024045183A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024045183A5 (https=) | ||
| JP2020007367A5 (https=) | ||
| JP7476161B2 (ja) | 凍結乾燥リポソーム | |
| DK2508170T3 (en) | LIPOSOM OF IRINOTECAN OR ITS HYDROCHLORIDE AND ITS PROCEDURE | |
| JP2014532623A5 (https=) | ||
| JP6216721B2 (ja) | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 | |
| JP3501289B2 (ja) | 医薬処方 | |
| US20080279927A1 (en) | Non-Pegylated Long-Circulating Liposomes | |
| EP1539102A2 (en) | Pharmaceutically active lipid based formulation of sn38 | |
| JP2007522085A (ja) | 安定化されたトポテカンリポソーム組成物および方法 | |
| HU197988B (en) | Process for producing lyophilized pharmaceutical product containing anthracycline - glycoside - derivative | |
| CN102258470A (zh) | 盐酸阿霉素纳米脂质体制剂的制备 | |
| JP2025118720A5 (https=) | ||
| HUT77975A (hu) | Vízben oldhatatlan kamptotecinek lipid-komplexének liofilizátuma | |
| CN108495619A (zh) | 棘霉素制剂及其制备方法和使用方法 | |
| CN112137958A (zh) | 一种含阿霉素与免疫佐剂组合药物脂质体及其制备方法 | |
| JPS6248629A (ja) | アントラサイクリングリコシド溶液 | |
| JP2008534525A (ja) | リン脂質のポリエチレングリコール誘導体に包み込まれたアンスラサイクリン系抗腫瘍抗生物質のナノミセル製剤 | |
| CA2135265A1 (en) | Stable lyophilized thiotepa composition | |
| CN101744767A (zh) | 包含喜树碱类抗肿瘤药物的热敏脂质体制剂 | |
| JP2020521004A (ja) | ｃ（ＲＧＤ−ＡＣＰ−Ｋ）修飾血中滞留型リポソーム | |
| US20200368170A1 (en) | A lipid nanoparticle composition and a pharmaceutical composition for treating a hematoproliferative disorder | |
| HU210834B (en) | Method for the preparation pharmaceutical composition for the treatment of dermatitis | |
| WO1993023015A1 (en) | Liposomal aminoglycoside compositions and process for their preparation | |
| RU2179452C1 (ru) | Способ лечения злокачественных новообразований и комплексный препарат, обладающий противоопухолевым действием, для осуществления способа |